• Moderate to severe dyspareunia.

Contraindicated in:

• Undiagnosed abnormal genital bleeding
• Current or history of breast cancer.

Use Cautiously in:

• None reported.

GU: vaginal discharge.

Drug-Drug:

• None reported.

• Vaginal insert: 6.5 mg;

• Vag (Adults): Insert one vaginal insert at bedtime.

Intrarosa

• Inactive steroid that is converted into active androgens and/or estrogens. Exact mechanism in treatment of vulvar and vaginal atrophy in menopausal women not fully established.

• Reduced severity of dyspareunia.

Therapeutic Classification: n/a

Pharmacologic Classification:

Absorption: Unknown.

Distribution: Unknown.

Metabolism/Excretion: Metabolized via dehydrogenase, reductase, and aromatase to estradiol and testosterone.

Half-life: Unknown.

(reduction in severity of dyspareunia)

• Explain purpose of prasterone to patient. Instruct patient to read Instructions for Use before inserting prasterone.
• Inform patient that vaginal discharge and abnormal PAP smear findings may occur with prasterone.
• Advise patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care professional before taking other medications during therapy.

PRAS-ter-one